Winfield Associates’s bluebird bio BLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-198
Closed -$236K 146
2019
Q3
$236K Hold
198
0.12% 117
2019
Q2
$327K Sell
198
-8
-4% -$13.8K 0.17% 94
2019
Q1
$420K Buy
206
+4
+2% +$7.04K 0.22% 86
2018
Q4
$260K Sell
202
-62
-23% -$95.1K 0.16% 92
2018
Q3
$499K Hold
264
0.25% 77
2018
Q2
$537K Sell
264
-15
-5% -$34.2K 0.29% 70
2018
Q1
$618K Buy
279
+30
+12% +$76.3K 0.33% 67
2017
Q4
$574K Sell
249
-7
-3% -$14.2K 0.29% 78
2017
Q3
$455K Buy
256
+38
+17% +$53.1K 0.24% 83
2017
Q2
$296K Buy
218
+13
+6% +$15.7K 0.16% 100
2017
Q1
$242K Hold
205
0.14% 112
2016
Q4
$164K Sell
205
-66
-24% -$52.4K 0.1% 122
2016
Q3
$238K Hold
271
0.15% 105
2016
Q2
$152K Buy
271
+1
+0.4% +$566 0.1% 121
2016
Q1
$148K Buy
270
+1
+0.4% +$614 0.1% 115
2015
Q4
$224K Sell
269
-63
-19% -$62.9K 0.15% 99
2015
Q3
$368K Buy
332
+57
+21% +$104K 0.28% 77
2015
Q2
$600K Buy
275
+148
+117% +$301K 0.41% 63
2015
Q1
$199K Buy
127
+119
+1,488% +$157K 0.14% 113
2014
Q4
$9K Hold
8
0.01% 242
2014
Q3
$4K Hold
8
﹤0.01% 262
2014
Q2
$3K Buy
+8
New +$2.56K ﹤0.01% 289

Other funds holding BLUE

Winfield Associates's BLUE Position: Q4 2019 in Review

Winfield Associates sold out of bluebird bio (BLUE) in Q4 2019, closing a stake of 198 shares — an estimated $236K sold.

Winfield Associates first reported a position in BLUE in Q2 2014 and held it in 22 quarters. The position peaked at $618K in Q1 2018. 274 funds tracked by Wall St. Rank hold BLUE as of Q4 2019.

  • Winfield Associates reported no remaining bluebird bio position as of Q4 2019 after selling out during the quarter.
  • Winfield Associates sold 198 bluebird bio shares in Q4 2019, an estimated $236K.
  • Winfield Associates first reported a position in bluebird bio in Q2 2014 and held it in 22 quarters.
  • Winfield Associates's bluebird bio position peaked at $618K in Q1 2018.
  • 274 funds tracked by Wall St. Rank held bluebird bio as of Q4 2019.

Based on Winfield Associates's 13F filing for Q4 2019, filed 13 Jan 2020.